Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma - PubMed (original) (raw)
. 2015 Mar;122(1):145-50.
doi: 10.1007/s11060-014-1693-x. Epub 2015 Jan 11.
Affiliations
- PMID: 25575937
- DOI: 10.1007/s11060-014-1693-x
Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma
Victor A Levin et al. J Neurooncol. 2015 Mar.
Abstract
Bevacizumab (BEV, Avastin(®)) produces durable objective radiological responses of 20-26 %, median response durations of 16-18 weeks, and median overall survival (mOS) of 31-40 weeks. While the use of BEV is well-established, the lack of dose-response studies in glioblastoma (GBM) patients raises the question whether current dosing practice is optimal. As a result of differing approaches to BEV dosing that ranged from the FDA approved package insert dose of 10 mg/kg every 2 weeks to 7.5 mg/kg every 3-4 weeks, among physicians within Northern California Kaiser Permanente hospitals over 4+ years, we did an IRB-approved retrospective analysis of patients seen in Northern California Kaiser Permanente facilities and treated with BEV. Between September 1, 2008 and August 31, 2013, 181 patients received BEV for tumor progression/recurrence starting 2.6 weeks after completion of chemoradiation. The integrated BEV administered dose-week (AUCBEV) for all patients had a median AUCBEV of 3.6 mg·wk/kg). Maximum likelihood analysis found patients over 65 years did worse than younger patients (p = 0.004), women lived longer (p = 0.002), and patients treated below the AUCBEV did better than those treated above the median AUCBEV (p = 0.003). mOS for BEV starting 1 month after chemoradiation was 45 versus 68 weeks (p = 0.012) and BEV starting 3 months after chemoradiation was 40 versus 74 weeks (p = 0.0085). Dosing BEV at half the standard dose for progressive/recurrent GBM was at least equivalent to or, maybe better than standard dosing. Unexplained was the observation that females had longer OS with BEV than males.
Similar articles
- Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
Levin VA, Chan J, Datta M, Yee JL, Jain RK. Levin VA, et al. J Neurooncol. 2017 Sep;134(2):325-330. doi: 10.1007/s11060-017-2528-3. Epub 2017 Jun 19. J Neurooncol. 2017. PMID: 28631191 - Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS. Jakobsen JN, et al. J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12. J Neurooncol. 2018. PMID: 29330749 - Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS. Cloughesy T, et al. J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5. J Clin Oncol. 2017. PMID: 27918718 Clinical Trial. - Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
Tipping M, Eickhoff J, Ian Robins H. Tipping M, et al. J Clin Neurosci. 2017 Oct;44:101-106. doi: 10.1016/j.jocn.2017.06.070. Epub 2017 Jul 12. J Clin Neurosci. 2017. PMID: 28711289 Free PMC article. Review. - Use of bevacizumab in recurrent glioblastoma.
Ghiaseddin A, Peters KB. Ghiaseddin A, et al. CNS Oncol. 2015;4(3):157-69. doi: 10.2217/cns.15.8. Epub 2015 Apr 23. CNS Oncol. 2015. PMID: 25906439 Free PMC article. Review.
Cited by
- The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report.
Zhong W, Mao J, Wu D, Peng J, Ye W. Zhong W, et al. Front Pharmacol. 2024 Sep 4;15:1401000. doi: 10.3389/fphar.2024.1401000. eCollection 2024. Front Pharmacol. 2024. PMID: 39295944 Free PMC article. - Outcomes of 2-SSRS plus bevacizumab therapy strategy for brainstem metastases (BSM) over 2 cm3: a multi-center study.
Wang Z, Chen H, Chen Q, Zhu Y, Li M, Zhou J, Shi L. Wang Z, et al. Neurosurg Rev. 2024 Apr 2;47(1):137. doi: 10.1007/s10143-024-02369-1. Neurosurg Rev. 2024. PMID: 38564039 - Angiotensin-converting enzyme inhibitors for ovarian cancer? - a new adjuvant option or a silent trap.
Regulska K, Michalak M, Kolenda T, Kozłowska-Masłoń J, Guglas K, Stanisz B. Regulska K, et al. Rep Pract Oncol Radiother. 2023 Aug 28;28(4):551-564. doi: 10.5603/RPOR.a2023.0059. eCollection 2023. Rep Pract Oncol Radiother. 2023. PMID: 37795232 Free PMC article. Review. - A systematic review of targeted therapy for vestibular schwannoma in patients with _NF2-_related schwannomatosis.
Chiranth S, Langer SW, Poulsen HS, Urup T. Chiranth S, et al. Neurooncol Adv. 2023 Aug 16;5(1):vdad099. doi: 10.1093/noajnl/vdad099. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37706198 Free PMC article. Review. - Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
Fu M, Zhou Z, Huang X, Chen Z, Zhang L, Zhang J, Hua W, Mao Y. Fu M, et al. BMC Cancer. 2023 Jun 14;23(1):544. doi: 10.1186/s12885-023-11043-6. BMC Cancer. 2023. PMID: 37316802 Free PMC article. Review.
References
- J Clin Oncol. 2008 Sep 10;26(26):4359; author reply 4359-60 - PubMed
- Curr Opin Neurol. 2009 Dec;22(6):633-8 - PubMed
- Oncologist. 2009 Nov;14(11):1131-8 - PubMed
- J Clin Oncol. 2009 Feb 10;27(5):740-5 - PubMed
- Cancer. 2010 Nov 15;116(22):5297-305 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials